FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza

Regeneron (REGN) secured FDA approval to expand the label of its cholesterol drug Evkeeza to include children aged 1 to under 5 with homozygous familial hypercholesterolemia (HoFH), adding to its niche market presence and generating $72.1 million in U.S. sales in H1 2025. This positive development offers incremental revenue as REGN faces significant top-line pressure from declining sales of its lead drug, Eylea, due to competition from Roche's Vabysmo, which has contributed to a 20.5% year-to-date stock decline. To counter this, Regeneron is actively diversifying its portfolio through its higher-dose Eylea HD, its share of Dupixent profits, and an advancing oncology pipeline.

Analysis

Regeneron has secured a positive but incremental regulatory win with the FDA's approval to expand its cholesterol drug Evkeeza's label to children aged one to five with the rare disease homozygous familial hypercholesterolemia (HoFH). While this broadens the drug's addressable market, its current financial contribution is modest, generating $72.1 million in U.S. sales in the first half of 2025. The more critical narrative for Regeneron remains the significant top-line pressure on its primary revenue driver, Eylea, which is facing intense competition from Roche's Vabysmo. This competitive headwind is the principal factor behind the stock's 20.5% year-to-date decline, a stark underperformance against the industry's 3.9% growth. In response, management is executing a multi-pronged diversification strategy. This includes the successful launch of a higher-dose Eylea HD, which saw sales surge 29% in the second quarter, the continued top-line contribution from its profit-sharing agreement with Sanofi for the high-performing drug Dupixent, and the expansion of its oncology portfolio through Libtayo and the newly approved Lynozyfic.

Key Decisions for Investors

• Investors should closely monitor the sales trajectory of Regeneron's growth drivers—Eylea HD, Dupixent, and the oncology portfolio—to assess if their momentum can successfully offset the continued revenue erosion of legacy Eylea from Roche's Vabysmo.
• Given the stock's significant 20.5% year-to-date underperformance, the current valuation likely prices in the Eylea headwinds, presenting a potential entry point for those confident in the diversification strategy's long-term success.
• Pay close attention to the upcoming PDUFA target action date in October for the potential label expansion of the oncology drug Libtayo, as a positive decision could serve as a key catalyst and validate the company's revenue diversification efforts.